

**Amendments to the Specification:**

Page 1, before line 4, the paragraph beginning with "Background of the Invention" insert the following title and paragraph:

PRIORITY CLAIM

Q1 This is a U.S. national stage of application No. PCT/US99/23014 filed on October 10, 1999, which claimed the priority date of U.S. Provisional Application No. 60/102,869 filed on October 02, 1998.

Please add an abstract on a separate sheet as follows:

ABSTRACT OF THE DISCLOSURE

Q2 Methods for the prevention of adhesion formation involve the administration of therapeutic formulations to a patient which include antibodies to TIMP-1 or TIMP-1 antisense oligonucleotides. The formulations can also include suitable carriers, such as a hyaluronic acid matrix, for optimal administration. The treatment procedure can be initiated and monitored by a diagnostic procedure which involves the detection of elevated levels of TIMP-1 in a patient.